Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H22N4O4S.ClH |
Molecular Weight | 474.96 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.O=C1CSC(=O)N1CC2=CC3=C(NC(=O)\C3=C/C4=CC(CN5CCOCC5)=CN4)C=C2
InChI
InChIKey=FPSAJUOIYZSJJA-NAIZSXBXSA-N
InChI=1S/C22H22N4O4S.ClH/c27-20-13-31-22(29)26(20)12-14-1-2-19-17(8-14)18(21(28)24-19)9-16-7-15(10-23-16)11-25-3-5-30-6-4-25;/h1-2,7-10,23H,3-6,11-13H2,(H,24,28);1H/b18-9-;
Molecular Formula | C22H22N4O4S |
Molecular Weight | 438.499 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P08581 Gene ID: 4233.0 Gene Symbol: MET Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
1.0 nM [IC50] | ||
Target ID: P30530 Gene ID: 558.0 Gene Symbol: AXL Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
7.0 nM [IC50] | ||
Target ID: Q12866 Gene ID: 10461.0 Gene Symbol: MERTK Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
2.0 nM [IC50] | ||
Target ID: CHEMBL2095217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
|||
Target ID: CHEMBL4895 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26555154 |
7.0 nM [IC50] | ||
Target ID: CHEMBL3717 |
1.0 nM [IC50] | ||
18.0 nM [IC50] | |||
Target ID: CHEMBL4142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
17.0 nM [IC50] | ||
Target ID: CHEMBL2742 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23804704 |
15.0 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. | 2013 Sep |
|
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. | 2017 Aug |
|
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy. | 2017 Oct |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:43:34 GMT 2023
by
admin
on
Sat Dec 16 11:43:34 GMT 2023
|
Record UNII |
ALUH60KSL9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALUH60KSL9
Created by
admin on Sat Dec 16 11:43:34 GMT 2023 , Edited by admin on Sat Dec 16 11:43:34 GMT 2023
|
PRIMARY | |||
|
101043621
Created by
admin on Sat Dec 16 11:43:34 GMT 2023 , Edited by admin on Sat Dec 16 11:43:34 GMT 2023
|
PRIMARY | |||
|
1265966-31-1
Created by
admin on Sat Dec 16 11:43:34 GMT 2023 , Edited by admin on Sat Dec 16 11:43:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |